Drug Sponsors

Sophiris Bio files for proposed IPO

Wednesday, February 20, 2013 11:24 AM

Sophiris Bio, a La Jolla, Calif.-based biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market.

More... »

Novartis, Dr. Vasella cancel non-compete agreement

Wednesday, February 20, 2013 09:29 AM

The Novartis board of directors and Dr. Daniel Vasella, chairman of the company’s board, have agreed to cancel Vasella’s non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after Vasella steps down as chairman of the board on February 22, 2013.

More... »

Dako, Pfizer collaborate on companion diagnostics

Thursday, February 14, 2013 08:00 AM

Dako, a tissue-based cancer diagnostics company based in Denmark, has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.

More... »

Reckitt Benckiser, BMS collaborate on Latam OTC

Wednesday, February 13, 2013 02:33 PM

Reckitt Benckiser Group has signed a three year collaboration agreement with Bristol-Myers Squibb (BMS) for a number of market-leading over-the-counter (OTC) consumer health care brands in Brazil, Mexico and certain other parts of Latin America, with an option to purchase at the end of the three year period.

More... »

e-Therapeutics to raise $62 million for cancer drug, network pharmacology platform

Monday, February 11, 2013 02:08 PM

Drug discovery and development company e-Therapeutics has proposed raising $62 million through an issue of new ordinary shares to existing and new institutional investors.

More... »

Ampio forms Luoxis Diagnostics to commercialize ORP tech

Monday, February 11, 2013 09:25 AM

Luoxis Diagnostics, a newly incorporated subsidiary of Ampio Pharmaceuticals, a biopharmaceutical company focused on prevalent inflammatory diseases, has initiated its operations that will initially be funded through a private placement, with Ampio maintaining approximately 80% ownership post financing.

More... »

Sun Pharma, Taro terminate proposed merger

Friday, February 8, 2013 01:08 PM

Sun Pharmaceutical Industries, an India-based specialty pharmaceutical company, and Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, have  mutually  agreed  to  terminate  their  merger  agreement,  announced  in  August  2012,  pursuant  to which all shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.

More... »

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Gilead Sciences acquires YM BioSciences

Wednesday, February 6, 2013 11:12 AM

The Supreme Court of Nova Scotia has issued a final order approving the previously announced plan involving YM BioSciences, Gilead Sciences and Nova Scotia Limited, a wholly-owned subsidiary of Gilead. Nova Scotia Limited will acquire all of the issued and outstanding common shares of YM BioSciences for cash consideration of $2.95 per common share.

More... »

Idenix Pharmaceuticals cancels IDX184 and IDX19368 programs for HCV

Wednesday, February 6, 2013 09:45 AM

Idenix Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the company had previously filed an IND but had not initiated patient dosing.

More... »